Marker Therapeutics, Inc.

Daily Archives: Wednesday, October 10, 2018

Mayo Clinic Lands $11 Million Grant to Study Breast Cancer Immunotherapy

The Department of Defense awarded more than $11 million for this Jacksonville study.

Read More

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.

Read More